IL33 and systemic lupus erythematosus: In animal studies, exogenous IL-33 induced the B cell activating factor (30), a growth factor implicated in SLE, and MRL/lpr lupus–prone mice treated with anti–IL-33 antibody have reduced renal inflammation and serum autoantibodies (31).